Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma
findings from the prospective MCC-TRIM registry.
Becker JC, Mahmoudpour SH, Schadendorf D, Leiter U, Meier F, Herbst R, Grabbe S, Gebhardt C, Ziller F, Pföhler C, Mohr P, Zimmer L, Boutmy E, Oksen D, Kearney M, Ruth K, Hoff S, Shlaen M, Ugurel S
British Journal of DermatologyIn the feed 10 Oct 2026, published online 10 Oct 2026, issue 2026 Oct 10, added to PubMed 10 Oct 2026
Topics: Skin cancer & tumors
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42855830 · DOI 10.1093/bjd/ljag445